Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • The Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

Annual Reports

Investors

Investors

  • Overview
  • News Releases
  • The Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • Financial Reports

  • Annual Reports
  • Quarterly Reports
Filter Filings:
Date Form Description Docs XBRL Pages
01/25/07 10-K/A Annual report pursuant to section 13 and 15(d)
Related Documents
EX-31.1
EX-31.2
HTML PDF 10
01/16/07 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF 60
01/31/06 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-3.2
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF 59
01/17/06 NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT HTML PDF 3
04/22/05 10-K/A Annual report pursuant to section 13 and 15(d)
Related Documents
EX-31.1
EX-31.2
HTML PDF 13
01/18/05 10-K/A Annual report pursuant to section 13 and 15(d)
Related Documents
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF 51
01/18/05 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-10.17
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF 59
01/18/05 NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT HTML PDF 3
12/22/03 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-23
EX-23
EX-31
EX-31
EX-32
EX-32
HTML PDF 51
02/13/03 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-23
EX-23
EX-99
EX-99
HTML PDF 49
RSS
  • << Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Feb 23, 2026

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Read More...
Feb 9, 2026

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Read More...
Feb 2, 2026

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Read More...
Copyrights © 2026 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap